search
Back to results

Effectiveness of Group Cognitive Behavioral Therapy for Psychological Sub-health (EGCBTPS)

Primary Purpose

Mental Suffering

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Group Cognitive Behavioral Therapy (GCBT)
Sponsored by
Jiangsu Province Nanjing Brain Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mental Suffering focused on measuring mental sub-health, Group Cognitive Behavioral Therapy (GCBT), wearable devices, EMA

Eligibility Criteria

16 Years - 35 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: A total of > 5 on PHQ-9 or a total of > 5 on GAD-7 Exclusion Criteria: Acute suicidal thoughts, With a severe or potentially confounding psychiatric disorder (e.g. psychosis, substance misuse).

Sites / Locations

  • Affiliated Nanjing Brain Hospital, Nanjing Medical UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

The clinical response of the group cognitive behavioural therapy

The alterations of behavior and physiological features in the group cognitive behavioral therapy.

Arm Description

A randomized controlled study of GCBT with one-month and six-month post-treatment follow-up was conducted to explore the short- and long-term efficacy of GCBT on mental sub-health

To understand the possible biological mechanism underlying the efficacy of group cognitive behavioral therapy by analyzing alterations of the alterations of behaviors and Physiological features in the group cognitive behavioral therapy features.

Outcomes

Primary Outcome Measures

Change from baseline in depressive symptoms assessed by the Patient Health Questionnaire-9 (PHQ-9; range: 0-27) at 4th weeks, 8th weeks, 28th weeks.
The total scores of these questionnaires were interpreted as follows: normal (0-4), mild (5-9), moderate (10-14), and severe (15-27) depression.
Change from baseline in anxiety symptoms assessed by the Generalized Anxiety Disorder-7 (GAD-7, range: 0-21) at 4th weeks, 8th weeks, 28th weeks.
The total scores of these questionnaires were interpreted as follows: normal (0-4), mild (5-9), moderate (10-14), and severe (15-21) anxiety.
Change from baseline in insomnia symptoms assessed by the Insomnia Severity Index (ISI; range: 0-28) at 4th weeks, 8th weeks and 28th weeks.
The total scores of these questionnaires were interpreted as follows: normal (0-7), mild (8-14), moderate (15-21), and severe (22-28) insomnia.
Change from baseline in perceived stress assessed by the Perceived Stress Scale-14 (PSS-14; range: 0-56) at 4th weeks, 8th weeks and 28th weeks.
The total scores of these questionnaires were interpreted as follows: normal (0-28), moderate (29-42), severe (43-56).
Change from baseline in suicidal ideation assessed by the Beck Scale for Suicide (BSS-14; range: 0-38) at 4th weeks, 8th weeks and 28th weeks.
The total scores of these questionnaires were interpreted as follows: no or low suicidal ideation (0-8), moderate suicidal ideation(9-16), high suicidal ideation (17-38).

Secondary Outcome Measures

Change from PPG, ACC, heart rate, blood oxygen, sleep time, RRI, step during intervention
The sensor data collection time period from 7am to 9pm
Change from daily mood and energy during intervention
Mood and energy are assessed by a single item each, "On a scale of 1 (very happy) to 7 (very sad), how is your mood right now?" "On a scale of 1 (very tired) to 7 (energetic), how is your energy right now?"

Full Information

First Posted
June 13, 2023
Last Updated
June 13, 2023
Sponsor
Jiangsu Province Nanjing Brain Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05913349
Brief Title
Effectiveness of Group Cognitive Behavioral Therapy for Psychological Sub-health
Acronym
EGCBTPS
Official Title
Effectiveness of Group Cognitive Behavioral Therapy for Psychological Sub-health: A Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 20, 2021 (Actual)
Primary Completion Date
September 1, 2023 (Anticipated)
Study Completion Date
January 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jiangsu Province Nanjing Brain Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Mental health has become an increasing concern, especially since the beginning of the COVID-19 pandemic. However, not all individuals in mental suboptimal states require pharmacological treatment. Cognitive Behavioral Therapy(CBT) can achieve its therapeutic effect by improving activation patterns of the brain's internal networks to promote self-regulation. The study was designed as a randomized clinical trial with two groups, the GCBT group and the Waiting group, in a state of mental subluxation. the GCBT group received both self-help therapy and on-site guidance, while the Waiting group received the GCBT intervention after treatment in the GCBT group. Data collection was conducted by trained, certified and qualified personnel. The study was designed to use assessment wearable devices (WD) and mobile apps (MA) for behavioral data and EMA collection during treatment, and the extracted behavioral characteristics were used as objective indicators for long-term and short-term efficacy assessment of GCBT, further understand the possible biological mechanism underlying the efficacy of GCBT by analyzing digital biomarkers.
Detailed Description
This study is a double-blind randomized controlled trial designed to assess the efficacy of GCBT compared to a waiting group for mental sub-health. Participants will be randomly (1:1) assigned to the GCBT group and the waiting group. All participants will receive 4 sessions (1 session per week) of 90 minutes each for 4 weeks.The GCBT group will receive cognitive behavioral therapy at the 1st-4th weeks, while the waiting group will receive cognitive behavioral therapy at the 5th-8th weeks. Before GCBT (baseline) and after GCBT (4th weeks, 8th weeks, 28th weeks), both groups will be assessed for clinical symptoms; during the 4 weeks of the intervention, we will collect sensor data and daily diary feedback. The GCBT is mainly divided into four stages, and each stage has a topic. The topic of each stage as follow:# understanding depression, anxiety, and CBT;# understanding automatic thinking and negative automatic thinking;# identifying and correcting negative automatic thinking identification; identifying and correcting intermediate beliefs;#understanding core beliefs and mastering correction techniques.The purposes of the present study are to: 1) evaluate the clinical response the GCBT in mental sub-health. 2) further understand the possible biological mechanism underlying the efficacy of GCBT by analyzing digital biomarkers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mental Suffering
Keywords
mental sub-health, Group Cognitive Behavioral Therapy (GCBT), wearable devices, EMA

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
The clinical response of the group cognitive behavioural therapy
Arm Type
Experimental
Arm Description
A randomized controlled study of GCBT with one-month and six-month post-treatment follow-up was conducted to explore the short- and long-term efficacy of GCBT on mental sub-health
Arm Title
The alterations of behavior and physiological features in the group cognitive behavioral therapy.
Arm Type
Experimental
Arm Description
To understand the possible biological mechanism underlying the efficacy of group cognitive behavioral therapy by analyzing alterations of the alterations of behaviors and Physiological features in the group cognitive behavioral therapy features.
Intervention Type
Behavioral
Intervention Name(s)
Group Cognitive Behavioral Therapy (GCBT)
Intervention Description
Group cognitive behavioral therapy can achieve its therapeutic effect by enhancing emotion regulation and cognitive control, and by improving the activation patterns of the brain's internal networks to promote self-regulation. This can help individuals better manage emotional fluctuations in daily life, resulting in further improvement of depressive and anxious symptoms.
Primary Outcome Measure Information:
Title
Change from baseline in depressive symptoms assessed by the Patient Health Questionnaire-9 (PHQ-9; range: 0-27) at 4th weeks, 8th weeks, 28th weeks.
Description
The total scores of these questionnaires were interpreted as follows: normal (0-4), mild (5-9), moderate (10-14), and severe (15-27) depression.
Time Frame
Baseline, 4th weeks, 8th weeks and 28th weeks
Title
Change from baseline in anxiety symptoms assessed by the Generalized Anxiety Disorder-7 (GAD-7, range: 0-21) at 4th weeks, 8th weeks, 28th weeks.
Description
The total scores of these questionnaires were interpreted as follows: normal (0-4), mild (5-9), moderate (10-14), and severe (15-21) anxiety.
Time Frame
Baseline, 4th weeks, 8th weeks and 28th weeks
Title
Change from baseline in insomnia symptoms assessed by the Insomnia Severity Index (ISI; range: 0-28) at 4th weeks, 8th weeks and 28th weeks.
Description
The total scores of these questionnaires were interpreted as follows: normal (0-7), mild (8-14), moderate (15-21), and severe (22-28) insomnia.
Time Frame
Baseline, 4th weeks, 8th weeks and 28th weeks
Title
Change from baseline in perceived stress assessed by the Perceived Stress Scale-14 (PSS-14; range: 0-56) at 4th weeks, 8th weeks and 28th weeks.
Description
The total scores of these questionnaires were interpreted as follows: normal (0-28), moderate (29-42), severe (43-56).
Time Frame
Baseline, 4th weeks, 8th weeks and 28th weeks
Title
Change from baseline in suicidal ideation assessed by the Beck Scale for Suicide (BSS-14; range: 0-38) at 4th weeks, 8th weeks and 28th weeks.
Description
The total scores of these questionnaires were interpreted as follows: no or low suicidal ideation (0-8), moderate suicidal ideation(9-16), high suicidal ideation (17-38).
Time Frame
Baseline, 4th weeks, 8th weeks and 28th weeks
Secondary Outcome Measure Information:
Title
Change from PPG, ACC, heart rate, blood oxygen, sleep time, RRI, step during intervention
Description
The sensor data collection time period from 7am to 9pm
Time Frame
During the treatment period
Title
Change from daily mood and energy during intervention
Description
Mood and energy are assessed by a single item each, "On a scale of 1 (very happy) to 7 (very sad), how is your mood right now?" "On a scale of 1 (very tired) to 7 (energetic), how is your energy right now?"
Time Frame
At 7am and 9pm daily during the treatment period

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: A total of > 5 on PHQ-9 or a total of > 5 on GAD-7 Exclusion Criteria: Acute suicidal thoughts, With a severe or potentially confounding psychiatric disorder (e.g. psychosis, substance misuse).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yang Wang, PHD
Phone
02418851071224
Email
yangwang201224@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fei Wang Study Chair, PHD
Organizational Affiliation
Affiliated Nanjing Brain Hospital, Nanjing Medical University
Official's Role
Study Chair
Facility Information:
Facility Name
Affiliated Nanjing Brain Hospital, Nanjing Medical University
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fei Wang, PHD
Phone
86-025-83295957
Email
fei.wang@yale.edu
First Name & Middle Initial & Last Name & Degree
Yang Wang, PHD
Phone
86-18851071224
Email
yangwang201224@163.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effectiveness of Group Cognitive Behavioral Therapy for Psychological Sub-health

We'll reach out to this number within 24 hrs